These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 8017475)

  • 1. Time course of the decline in renal function in cyclosporine-treated heart transplant recipients.
    Zietse R; Balk AH; vd Dorpel MA; Meeter K; Bos E; Weimar W
    Am J Nephrol; 1994; 14(1):1-5. PubMed ID: 8017475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term improvement in renal function after cyclosporine reduction in renal transplant recipients with histologically proven chronic cyclosporine nephropathy.
    Mourad G; Vela C; Ribstein J; Mimran A
    Transplantation; 1998 Mar; 65(5):661-7. PubMed ID: 9521200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conversion of liver transplant recipients on cyclosporine with renal impairment to mycophenolate mofetil.
    Herrero JI; Quiroga J; Sangro B; Girala M; Gómez-Manero N; Pardo F; Alvárez-Cienfuegos J; Prieto J
    Liver Transpl Surg; 1999 Sep; 5(5):414-20. PubMed ID: 10477843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results.
    Krämer BK; Montagnino G; Del Castillo D; Margreiter R; Sperschneider H; Olbricht CJ; Krüger B; Ortuño J; Köhler H; Kunzendorf U; Stummvoll HK; Tabernero JM; Mühlbacher F; Rivero M; Arias M;
    Nephrol Dial Transplant; 2005 May; 20(5):968-73. PubMed ID: 15741208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and side-effects of cyclosporine dose monitoring with levels 6 h after the morning dose in heart transplant patients.
    Cantarovich M; Besner JG; Fitchett DH; Latter DA
    Clin Transplant; 1997 Oct; 11(5 Pt 1):399-405. PubMed ID: 9361930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study.
    Oberbauer R; Kreis H; Johnson RW; Mota A; Claesson K; Ruiz JC; Wilczek H; Jamieson N; Henriques AC; Paczek L; Chapman J; Burke JT;
    Transplantation; 2003 Jul; 76(2):364-70. PubMed ID: 12883194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progressive histologic injury in kidneys from heart and liver transplant recipients receiving cyclosporine.
    Falkenhain ME; Cosio FG; Sedmak DD
    Transplantation; 1996 Aug; 62(3):364-70. PubMed ID: 8779684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Everolimus and reduced cyclosporine trough levels in maintenance heart transplant recipients.
    Schweiger M; Wasler A; Prenner G; Stiegler P; Stadlbauer V; Schwarz M; Tscheliessnigg K
    Transpl Immunol; 2006 Jun; 16(1):46-51. PubMed ID: 16701176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The natural history of renal function following orthotopic heart transplant.
    Al Aly Z; Abbas S; Moore E; Diallo O; Hauptman PJ; Bastani B
    Clin Transplant; 2005 Oct; 19(5):683-9. PubMed ID: 16146562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can cyclosporine blood level be reduced to half after heart transplantation?
    Wang SS; Chou NK; Chi NH; Huang SC; Wu IH; Wang CH; Yu HY; Chen YS; Tsao CI; Ko WJ; Shun CT
    Transplant Proc; 2010 Apr; 42(3):930-3. PubMed ID: 20430207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Everolimus with reduced cyclosporine versus MMF with standard cyclosporine in de novo heart transplant recipients.
    Lehmkuhl HB; Arizon J; Viganò M; Almenar L; Gerosa G; Maccherini M; Varnous S; Musumeci F; Hexham JM; Mange KC; Livi U;
    Transplantation; 2009 Jul; 88(1):115-22. PubMed ID: 19584690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term efficacy and safety of cyclosporine in renal-transplant recipients.
    Burke JF; Pirsch JD; Ramos EL; Salomon DR; Stablein DM; Van Buren DH; West JC
    N Engl J Med; 1994 Aug; 331(6):358-63. PubMed ID: 8028616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does everolimus associated with a low dose of cyclosporine in long-term cardiac transplant recipients improve renal function? Initial experience.
    Boffini M; Sansone F; Patanè F; Bonato R; Ribezzo M; Iacovino C; Comoglio C; Rinaldi M
    Transplant Proc; 2009 May; 41(4):1349-52. PubMed ID: 19460557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-dose cyclosporine therapy in triple-drug immunosuppression for heart transplant recipients.
    Hausen B; Demertzis S; Rohde R; Albes JM; Schäfers HJ; Borst HG
    Ann Thorac Surg; 1994 Oct; 58(4):999-1004. PubMed ID: 7944822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early steroid withdrawal protocol with basiliximab, cyclosporine and mycophenolate mofetil in renal-transplant recipients.
    Kato Y; Tojimbara T; Iwadoh K; Koyama I; Nanmoku K; Kai K; Sannomiya A; Nakajima I; Fuchinoue S; Teraoka S
    Int Immunopharmacol; 2006 Dec; 6(13-14):1984-92. PubMed ID: 17161352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safe conversion to cicloral, a generic cylosporine, in both stable and de novo renal transplant recipients.
    Kahn D; Muller E; Pascoe M
    Saudi J Kidney Dis Transpl; 2010 May; 21(3):426-32. PubMed ID: 20427863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of basiliximab and cyclosporine in heart transplant patients with pre-operative renal dysfunction.
    Delgado DH; Miriuka SG; Cusimano RJ; Feindel C; Rao V; Ross HJ
    J Heart Lung Transplant; 2005 Feb; 24(2):166-9. PubMed ID: 15701432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 1-year randomized controlled study of everolimus versus mycophenolate mofetil with reduced-dose cyclosporine in maintenance heart transplant recipients.
    Bara C; Dengler T; Hack MA; Ladenburger S; Lehmkuhl HB
    Transplant Proc; 2013; 45(6):2387-92. PubMed ID: 23953553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. C2 monitoring in maintenance renal transplant recipients: is it worthwhile?
    Midtvedt K; Fauchald P; Bergan S; Høieggen A; Hallan S; Svarstad E; Bergrem H; Eriksen BO; Pfeffer PF; Dalen I; Leivestad T
    Transplantation; 2003 Oct; 76(8):1236-8. PubMed ID: 14578761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus.
    Levy G; Grazi GL; Sanjuan F; Wu Y; Mühlbacher F; Samuel D; Friman S; Jones R; Cantisani G; Villamil F; Cillo U; Clavien PA; Klintmalm G; Otto G; Pollard S; McCormick PA
    Liver Transpl; 2006 Oct; 12(10):1464-72. PubMed ID: 17004259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.